Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs JPMorgan Chase & Co — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while JPMorgan Chase & Co trades at $332.99 (market cap $880.98B). The key difference: JPMorgan Chase & Co is far larger — about 70× Halozyme Therapeutics Inc. Common Stock's market cap, and JPMorgan Chase & Co pays a 1.99% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and JPMorgan Chase & Co for 127 Days on average.
| HALO | JPM | |
|---|---|---|
Market Cap | $12.58B | $880.98B |
Volume | 2,179,278 | 7,721,661 |
Sector | Health | Financials |
52-Week High | $115.22 | $365.18 |
52-Week Low | $61.63 | $282.84 |
Typical Hold Time | 1 Days | 127 Days |
Enterprise Value | $14.49B | $1.82T |
Dividend Yield | — | 1.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JPMorgan Chase & Co. (JPM) trades at $331.42, up 0.56% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growing to $181.85B in 2025. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target.
Outlook remains positive due to robust profitability and institutional confidence, though risks include geopolitical tensions and cybersecurity threats highlighted in recent news. The stock offers value with upside potential, but investors should monitor cash flow trends and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
